Late dexamethazone

ApprovedSmall molecule

CClinAmygate

Late dexamethazone is one of 8 small molecule programs targeting Anosmia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnosmiaActive, not recruiting

AnosmiaApproved

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Anosmia

#DrugCompanyPhaseTrials

Theo-Dur

Pfizer

Approved

1 2

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—3

Stromectol

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—4

Cerebrolysin

EEver Neuro Pharma GmbH

Approved

2 5

Pulmicort

SSalix

Phase 2

1 6

Late dexamethazone

CClinAmygate

Approved

1 7

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 1

1 8

N-Acetyl Cyteien

SStanford University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Anosmia1 trial

Anosmia and / or Ageusia and Early Corticosteroid Use

Unknown status·CClinAmygate·Phase 4·NCT04528329·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Late dexamethazone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Late dexamethazone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Late dexamethazone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ClinAmygate company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: CClinAmygate

Late dexamethazone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Anosmia1 trial

References

Drug Info

Quick Facts

Related News